Adage Capital Partners
RNAM

Adage Capital Partners’s Avidity Biosciences RNAM Stock Holding History

Adage Capital Partners’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,630,966
Closed -$190M – 1058
2025
Q4 		$190M Buy
2,630,966
+1,430,966
+119% +$92.4M 0.29% 63
2025
Q3 		$52.3M Sell
1,200,000
-327,000
-21% -$13.2M 0.08% 230
2025
Q2 		$43.4M Sell
1,527,000
-618,881
-29% -$18.4M 0.07% 266
2025
Q1 		$63.3M Sell
2,145,881
-606,063
-22% -$18.9M 0.12% 175
2024
Q4 		$80M Sell
2,751,944
-327,430
-11% -$13.7M 0.14% 141
2024
Q3 		$141M Sell
3,079,374
-317,608
-9% -$13.8M 0.25% 75
2024
Q2 		$139M Buy
3,396,982
+996,937
+42% +$28.6M 0.26% 73
2024
Q1 		$61.2M Buy
2,400,045
+800,045
+50% +$12.5M 0.12% 191
2023
Q4 		$14.5M Buy
1,600,000
+300,000
+23% +$2.01M 0.03% 517
2023
Q3 		$8.29M Buy
1,300,000
+550,000
+73% +$4.74M 0.02% 601
2023
Q2 		$8.32M Buy
+750,000
New +$9.41M 0.02% 599
2020
Q3 		– Sell
-25,000
Closed -$707K – 800
2020
Q2 		$707K Buy
+25,000
New +$721K ﹤0.01% 709

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Adage Capital Partners's RNAM Position: Q1 2026 in Review

Adage Capital Partners sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 2,630,966 shares — an estimated $190M sold.

Adage Capital Partners first reported a position in RNAM in Q2 2020 and held it in 12 quarters. The position peaked at $190M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Adage Capital Partners reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Adage Capital Partners sold 2,630,966 Avidity Biosciences shares in Q1 2026, an estimated $190M.
  • Adage Capital Partners first reported a position in Avidity Biosciences in Q2 2020 and held it in 12 quarters.
  • Adage Capital Partners's Avidity Biosciences position peaked at $190M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.